ASX:MSBBiotechs
Mesoblast (ASX:MSB) Is Up 8.0% After Ryoncil’s Early Adoption And Adult Expansion Push - Has The Bull Case Changed?
Mesoblast recently reported encouraging real-world use of its FDA-approved cell therapy Ryoncil for children with steroid-refractory acute graft-versus-host disease, alongside significant progress in payer coverage and transplant center onboarding since its 2025 launch.
The company is also moving to broaden Ryoncil’s use into the larger adult SR-aGvHD population, while advancing rexlemestrocel-L for chronic low back pain as a potential non-opioid option, underscoring how its cell therapy...